Tweet by Michael “Mike” Albert, MD Obesity is. CNS. Disorder

kItBIxpz_normal.jpg spacer.png
Michael “Mike” Albert, MD
⁦‪@MichaelAlbertMD‬⁩
logo_twitter-1497383721365.png
spacer_464x1-1582829598167.png
A reminder that obesity is primarily a nervous system disorder. The complications of obesity (think cardiometabolic) are often related to adipocyte dysfunction. Upstream, think nervous system. Downstream, think adipocyte.
7/30/22, 11:34 AM

Joseph Thornton

Tweet by Marion Koopmans on Graphics explain COVID control

04pk034twr75lw8wf3rr_normal.jpeg spacer.png
Marion Koopmans
⁦‪@MarionKoopmans‬⁩
logo_twitter-1497383721365.png
spacer_464x1-1582829598167.png
incredibly well written review of COVID19 along 6 false dichotomies. Must read for everyone with a real interest in Covid science . Spoiler: not black and wide but shades of grey and those need to be communicated. Really great work bmcinfectdis.biomedcentral.com/articles/10.11… ⁦‪@KindrachukJason‬⁩ pic.twitter.com/vv9nx5JP5I
8/15/22, 2:58 AM

Joseph Thornton

another view of borderline Personality disorder

Continuing our discussion..

The very notion of personality disorders is controversial . When we say someone has a disordered personality it comes across to some as a personal insult, yet we look at autism quite differently.

At core is the definition of chronic persistent use of maladaptive defense mechanisms, and we delegate intervention to longer term psychotherapy.

Another consideration – maybe this has been resolved and I just do not know enough child psychiatry – you will need to tell me.

      We know (believe) that temperaments are manifest in very early childhood and have biological underpinnings. It would seem to me that as various temperaments mater, they may progress to different types fo personality disorders. Thus if biologically based, then biological psychiatrists (my training) should have studied these conditions. I know of only 2 groups that did pursue it.

Long ago I worked on a DSM III validity study of personality disorders. The main finding was the dx is not stable if made in context of symptomatic Axis I disorder. However, even with personality traits, we as psychiatrists must learn how to navigate the emotions and behaviors.

I attach an old article by George Vaillant with some perspective.

JT

Joseph (Joe) E. Thornton, M.D., DFAPA
Clinical Associate Professor, Psychiatry
University of Florida College of Medicine
joethornton@ufl.edu

CONFIDENTIALITY NOTIFICATION: Please be advised! This e-mail message, including any attachments, has been created explicitly for the sole use of the intended recipient(s) and may contain confidential and privileged information. The materials in this message are private and may contain Protected Healthcare Information or other information of a sensitive nature. If you are not the intended recipient, be advised that any unauthorized use, disclosure, copying or the taking of any action in reliance on the contents of this information is strictly prohibited. If you have received this email in error, please immediately notify the sender via telephone or return mail. Any unauthorized review, use, disclosure, or distribution of such information is prohibited and will be upheld under the discretion of Federal and State law. If you have received this e-mail message in error and are not an intended recipient, please contact the sender via reply e-mail or phone and destroy all copies of the original message. Pursuant to ‘ FS 766.101, FS 395.0193, FS 395.0197, FS 766.1016 and other Statutes, this document is privileged and confidential. It is not subject to discovery. Please do NOT copy or release.

Vaillant GE 1992 Wisdom borderline.pdf

Mudra articles

I co-authored the first article with Vaughn.

The second articleby Ahonle focuses on the absence of increased suicide in patients deprescribed from opiates.

JT

Joseph (Joe) E. Thornton, M.D., DFAPA
Clinical Associate Professor, Psychiatry
University of Florida College of Medicine
joethornton@ufl.edu

CONFIDENTIALITY NOTIFICATION: Please be advised! This e-mail message, including any attachments, has been created explicitly for the sole use of the intended recipient(s) and may contain confidential and privileged information. The materials in this message are private and may contain Protected Healthcare Information or other information of a sensitive nature. If you are not the intended recipient, be advised that any unauthorized use, disclosure, copying or the taking of any action in reliance on the contents of this information is strictly prohibited. If you have received this email in error, please immediately notify the sender via telephone or return mail. Any unauthorized review, use, disclosure, or distribution of such information is prohibited and will be upheld under the discretion of Federal and State law. If you have received this e-mail message in error and are not an intended recipient, please contact the sender via reply e-mail or phone and destroy all copies of the original message. Pursuant to ‘ FS 766.101, FS 395.0193, FS 395.0197, FS 766.1016 and other Statutes, this document is privileged and confidential. It is not subject to discovery. Please do NOT copy or release.

Ahonle Mudra SA et al deprescribe without suicide .pdf

Vaughn IA et al 2019 Multispecialty Opioid Risk Reduction .pdf